TREM2 and Alzheimer disease: While immunotherapies and oligonucleotides targeting TREM2 activation and expression are major neuroinflammatory drug candidates in the next wave of potential AD therapies, it has become evident that TREM2 activity is context-dependent (i.e., disease state, tissue, and cell type).